HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Core Viewpoint - HUTCHMED (China) Limited has appointed Dr. Renu Bhatia as an Independent Non-executive Director, effective May 13, 2024, to enhance the Board's expertise in healthcare and finance sectors [1][2][3]. Group 1: Appointment Details - Dr. Bhatia has over 25 years of experience in healthcare, finance, fintech, and regulatory sectors, and is expected to provide valuable insights to the Board [1][2]. - The initial term of Dr. Bhatia's appointment will end at the next annual general meeting, with a director's fee of US$76,000 and US$8,000 for her role in the Technical Committee [4]. - Dr. Bhatia holds 16,000 ordinary shares in HUTCHMED, representing approximately 0.002% of its issued share capital [5]. Group 2: Background and Experience - Dr. Bhatia is the chairman and co-founder of Opharmic Technology (HK) Ltd, focusing on ultrasound technology for drug delivery, and co-founder of Asia Fintech Angels [2][3]. - She has held significant positions in public service and has a strong background in finance, having started her career at Goldman Sachs and HSBC Asset Management [3]. - Dr. Bhatia holds a Doctor of Medicine from the University of London, an MBA from Yale University, and a Postgraduate Diploma in Therapeutics and Medicine from The University of Hong Kong [3]. Group 3: Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [6]. - The company employs approximately 5,000 personnel, with a core team of about 1,800 in oncology/immunology [6].